Abstract
(Reprinted with permission from the Lancet 2019; 394: 939-51).
Highlights
Schizophrenia is a common debilitating disorder (1% of the world population are afflicted) with a huge burden for patients, which cost the USA US$155·7 billion in 2013.1,2 Antipsychotics are the mainstay of treatment,[3] but are associated with important side-effects that can Lancet 2019; 394: 939–51
Evidence before this study Treatment with antipsychotic drugs is the standard for the acute phase of schizophrenia according to most national and international guidelines
We searched PubMed for network meta-analyses on the acute treatment of schizophrenic patients with antipsychotics published between database inception and Oct 5, 2018
Summary
Published Online July 11, 2019 http://dx.doi.org/10.1016/ S0140-6736(19)31135-3 Because many antipsychotic drugs are available, according to WHO, understanding how the many substances compare with each other is important, ideally ranked in a hierarchy. Due to their diverging receptor binding profiles, different antipsychotics can vary considerably in their efficacy and side-effect profiles. We searched PubMed for network meta-analyses on the acute treatment of schizophrenic patients with antipsychotics published between database inception and Oct 5, 2018. We found no comprehensive and systematic network meta-analysis comparing older and newer antipsychotics for the acute treatment of schizophrenia over several efficacy and safety outcomes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
